芦可替尼作为治疗皮质类固醇难治性移植物抗宿主病的一种有前景的疗法。 - Suppr

Suppr

超能文献

Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.

作者信息

Assouan Deborah, Lebon Delphine, Charbonnier Amandine, Royer Bruno, Marolleau Jean-Pierre, Gruson Berengere

机构信息

Hématologie, Centre Hospitalier Universitaire d'Amiens, Amiens, France.

出版信息

Br J Haematol. 2018 Jun;181(5):687-689. doi: 10.1111/bjh.14679. Epub 2017 Apr 25.

DOI:10.1111/bjh.14679

PMID:28444730

Abstract

摘要

相似文献

Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.

Br J Haematol. 2018 Jun;181(5):687-689. doi: 10.1111/bjh.14679. Epub 2017 Apr 25.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. doi: 10.1016/j.bbmt.2019.04.003. Epub 2019 Apr 6.

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.

Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823.

Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.

Pediatr Dermatol. 2022 May;39(3):432-433. doi: 10.1111/pde.14965. Epub 2022 Mar 2.

Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study.

Am J Hematol. 2020 Sep;95(9):1075-1084. doi: 10.1002/ajh.25898. Epub 2020 Jul 6.

Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.

Pediatr Blood Cancer. 2020 Sep;67(9):e28233. doi: 10.1002/pbc.28233. Epub 2020 Jul 2.

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.

Biol Blood Marrow Transplant. 2019 Feb;25(2):265-269. doi: 10.1016/j.bbmt.2018.09.003. Epub 2018 Sep 8.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1576-82. doi: 10.1016/j.bbmt.2015.04.023. Epub 2015 May 16.

When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.

Clin Transplant. 2024 Jan;38(1):e15195. doi: 10.1111/ctr.15195. Epub 2023 Nov 21.

引用本文的文献

Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.

Paediatr Drugs. 2023 Sep;25(5):577-584. doi: 10.1007/s40272-023-00577-8. Epub 2023 Jun 7.

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.

PLoS One. 2022 Jul 29;17(7):e0271979. doi: 10.1371/journal.pone.0271979. eCollection 2022.

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.

Clin Oral Investig. 2022 May;26(5):4209-4216. doi: 10.1007/s00784-022-04393-1. Epub 2022 Feb 16.

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.

Sci Rep. 2021 Apr 19;11(1):8501. doi: 10.1038/s41598-021-88080-3.

Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge.

ACG Case Rep J. 2020 Dec 21;7(12):e00499. doi: 10.14309/crj.0000000000000499. eCollection 2020 Dec.

Ruxolitinib add-on in corticosteroid-refractory graft--host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients.

World J Clin Cases. 2020 Mar 26;8(6):1065-1073. doi: 10.12998/wjcc.v8.i6.1065.

Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.

Drugs. 2019 Sep;79(14):1499-1509. doi: 10.1007/s40265-019-01174-1.

Ruxolitinib for Therapy of Graft-versus-Host Disease.

Biomed Res Int. 2019 Mar 6;2019:8163780. doi: 10.1155/2019/8163780. eCollection 2019.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验